Any current/future new fundraising through debt or equity?

The company is currently net debt-free as of September 2023, with a net cash position of ₹3,109 million, primarily from IPO proceeds. For the planned expansion, including addition of approximately 1,400-1,450 beds over the next three years, the company has Capex plans of around ₹800 crore. The company does not expect to require any long-term loan capital to fund these projects and is sufficiently funded for this expansion. No specific mention of new equity fundraising beyond the recently completed IPO. Focus remains on sustainable growth using existing funds without additional debt or equity r

Any current/future capex/capital investment/strategic investment?

Planned Capex of around ₹800 crore over the next three years for adding approximately 1,400-1,450 beds. Expansion includes both greenfield (new construction) and brownfield projects (expansion of existing facilities). Capex may vary depending on the proportion of beds added through O&M (Operations & Management) model versus greenfield construction. The company is sufficiently funded for this expansion, with no expected need for additional long-term loans. Acquired adjacent land parcels at Greater Noida hospital and Noida Extension hospital to support organic expansion. Expect first capacity in

Future growth expectations in sales/revenue/volumes?

Revenue grew 36% YoY to ₹3,258 million in H1 FY24, with 34% YoY growth in Q2. Expect quarter-on-quarter top-line growth in coming quarters and years. Focus on increasing capacity utilization across existing hospitals except Noida, which is running high. Expansion plans to double bed capacity over 3-4 years via greenfield, brownfield, and acquisitions. Oncology services and robotic surgeries to commence in Q4 FY24, expected to boost revenues. International patient inflows from SAARC and CIS countries expected to grow significantly. Organ transplant and medical tourism businesses expanding, anti

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margins currently stand at 26%+ and are expected to grow due to the induction of international business, oncology, and higher specialties, which increase ARPOB (Average Revenue Per Occupied Bed). Plans to double bed capacity over the next 3-4 years, supporting revenue and margin expansion through organic and inorganic growth. Capex of around ₹800 Cr planned for adding about 1,400-1,450 beds, funded without long-term loans. International patient inflow and medical tourism expected to contribute significantly, with growth seen from SAARC and CIS countries. Oncology services and robotic su

Yatharth Hospit.Q2 FY24Healthcare Services

Yatharth Hospit. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,034P/E: 59.6Market Cap: ₹10.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Revenue grew 36% YoY to ₹3,258 million in H1 FY24, with 34% YoY growth in Q2.
Expect quarter-on-quarter top-line growth in coming quarters and years.
Focus on increasing capacity utilization across existing hospitals except Noida, which is running high.
Expansion plans to double bed capacity over 3-4 years via greenfield, brownfield, and acquisitions.
Oncology services and robotic surgeries to commence in Q4 FY24, expected to boost revenues.
International patient inflows from SAARC and CIS countries expected to grow significantly.
Organ transplant and medical tourism businesses expanding, anticipated to improve ARPOB and revenues.
New acquisitions (150-250 beds) planned before fiscal year-end to increase capacity and revenue.
Noida extension and Greater Noida hospitals poised for strong catchment growth aiding revenue increase.

Margin guidance

Category 3

EBITDA margins currently stand at 26%+ and are expected to grow due to the induction of international business, oncology, and higher specialties, which increase ARPOB (Average Revenue Per Occupied Bed).
Plans to double bed capacity over the next 3-4 years, supporting revenue and margin expansion through organic and inorganic growth.
Capex of around ₹800 Cr planned for adding about 1,400-1,450 beds, funded without long-term loans.
International patient inflow and medical tourism expected to contribute significantly, with growth seen from SAARC and CIS countries.
Oncology services and robotic surgeries expected to begin contributing from Q4 FY24, improving revenue and ARPOB.
Profit after Tax grew 70% YoY in H1 FY24 with a net debt-free status enhancing profitability.
Incremental EBITDA growth expected across facilities, with Noida Extension poised for higher ARPOB and contribution.
Overall, consistent quarter-on-quarter topline growth anticipated with margin expansion driven by specialty services.

See what Yatharth Hospit. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company is currently net debt-free as of September 2023, with a net cash position of ₹3,109 million, primarily from IPO proceeds.
For the planned expansion, including addition of approximately 1,400-1,450 beds over the next three years, the company has Capex plans of around ₹800 crore.
The company does not expect to require any long-term loan capital to fund these projects and is sufficiently funded for this expansion.
No specific mention of new equity fundraising beyond the recently completed IPO.
Focus remains on sustainable growth using existing funds without additional debt or equity raising at this point.

Order book

The transcript provided does not mention any details about current or expected order book or pending orders for Yatharth Hospitals and Trauma Care Services Ltd. The discussion primarily focuses on margins, EBITDA growth, CAPEX plans, occupancy levels, bed capacity expansion, government business, empanelment status, acquisitions, ARPOB, and specialty services growth. If you need information about order book or pending orders, that data is not available in the transcript pages shared.

See what Yatharth Hospit. management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned Capex of around ₹800 crore over the next three years for adding approximately 1,400-1,450 beds.
Expansion includes both greenfield (new construction) and brownfield projects (expansion of existing facilities).
Capex may vary depending on the proportion of beds added through O&M (Operations & Management) model versus greenfield construction.
The company is sufficiently funded for this expansion, with no expected need for additional long-term loans.
Acquired adjacent land parcels at Greater Noida hospital and Noida Extension hospital to support organic expansion.
Expect first capacity increase through hospital acquisition (150-250 beds) to be completed by fiscal year-end.
Expansion aimed at boosting specialties like oncology, organ transplants, and international patient business.
Robotic surgery equipment will be commissioned soon as part of oncology service expansion.

Track Yatharth Hospit. — get its next earnings analysis in your feed

How does Yatharth Hospit. rank vs peers in Healthcare Services?

Pro feature

ThisYatharth Hospit.

Rev 2Mar 3

See where Yatharth Hospit. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Yatharth Hospit. rank in Healthcare Services?

Compare Yatharth Hospit. against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Yatharth Hospit.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →